Zou W - Search Results

1

A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features.

Liu F, Wang H, Liu J, Zhou Z, Zheng D, Huang B, Su C, Zou W, Xu D, Tong X, Li J. Liu F, et al. Among authors: zou w. Cancer Med. 2019 Sep;8(11):5108-5115. doi: 10.1002/cam4.2418. Epub 2019 Jul 19. Cancer Med. 2019. PMID: 31322840 Free PMC article.

2

[Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients].

Li J, Luo S, Hong W, Zhou Z, Zou W. Li J, et al. Among authors: zou w. Zhonghua Zhong Liu Za Zhi. 2002 May;24(3):254-6. Zhonghua Zhong Liu Za Zhi. 2002. PMID: 12515619 Chinese.

3

[Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].

Li J, Luo SK, Hong WD, Zhou ZH, Zou WY. Li J, et al. Ai Zheng. 2003 Apr;22(4):346-9. Ai Zheng. 2003. PMID: 12703985 Chinese.

4

[Values of soluble thrombomodulin and von Willebrand factor judging reject reaction in liver transplantation].

Wen CG, Luo SK, He XS, Li J, Liu M, Zou WY, Peng AH. Wen CG, et al. Zhonghua Gan Zang Bing Za Zhi. 2003 May;11(5):295-7. Zhonghua Gan Zang Bing Za Zhi. 2003. PMID: 12773246 Chinese.

5

[Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].

Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK. Tong XZ, et al. Zhonghua Zhong Liu Za Zhi. 2006 Jul;28(7):545-8. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17147125 Clinical Trial. Chinese.

6

[Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].

Tong XZ, Xu DR, Zou WY, Li J, Luo SK, Peng AH, Zhang GC, Zheng D. Tong XZ, et al. Ai Zheng. 2007 Aug;26(8):914-8. Ai Zheng. 2007. PMID: 17697559 Free article. Chinese.

7

[Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects].

Zou WY, Xu DR, Su C, Li J, Luo SK. Zou WY, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(9):1660-2. Nan Fang Yi Ke Da Xue Xue Bao. 2008. PMID: 18819894 Chinese.

8

New targets of PS-341: BAFF and APRIL.

Li W, Li J, Su C, Zou WY, Luo S. Li W, et al. Among authors: zou wy. Med Oncol. 2010 Jun;27(2):439-45. doi: 10.1007/s12032-009-9230-z. Epub 2009 May 19. Med Oncol. 2010. PMID: 19452288

9

[Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease].

Xu DR, Su C, Zou WY, Xu HR, Huang S, Li J, Luo SK. Xu DR, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Apr;18(2):376-80. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010. PMID: 20416172 Chinese.

10

[Dynamic observations of beta-catenin in chronic myeloid leukemia and its relationship with cytogenetic response].

Zou WY, Xu DR, Su C, Chen M, Li J, Luo SK. Zou WY, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2010 Aug;30(8):1868-70, 1873. Nan Fang Yi Ke Da Xue Xue Bao. 2010. PMID: 20813688 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,663 results

Search Page

Filters